Privia Health Group (PRVA) Projected to Post Quarterly Earnings on Thursday

Key Points

• Privia Health Group (PRVA) is expected to announce its Q2 2025 earnings on August 7th, with analysts predicting earnings of $0.05 per share and revenue of $466.97 million.
• Recent analyst ratings show strong confidence in the stock, with a consensus rating of "Buy" and a target price of $28.38.
• CEO Parth Mehrotra and CFO David Mountcastle both sold shares recently, which represents a decrease in their ownership but highlights continued executive activity in the market.

Privia Health Group (NASDAQ:PRVA - Get Free Report) will likely be releasing its Q2 2025 earnings data before the market opens on Thursday, August 7th. Analysts expect Privia Health Group to post earnings of $0.05 per share and revenue of $466.97 million for the quarter.

Privia Health Group Stock Performance

Shares of PRVA traded up $0.65 on Monday, hitting $19.51. 337,860 shares of the stock traded hands, compared to its average volume of 811,677. Privia Health Group has a one year low of $16.47 and a one year high of $26.09. The company has a market capitalization of $2.38 billion, a PE ratio of 162.62, a P/E/G ratio of 3.02 and a beta of 0.80. The business has a 50 day simple moving average of $21.62 and a 200 day simple moving average of $22.92.

Insider Transactions at Privia Health Group

In other news, CEO Parth Mehrotra sold 13,773 shares of the company's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $24.99, for a total value of $344,187.27. Following the completion of the sale, the chief executive officer owned 423,143 shares of the company's stock, valued at approximately $10,574,343.57. This represents a 3.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO David Mountcastle sold 3,322 shares of the company's stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $24.99, for a total transaction of $83,016.78. Following the completion of the sale, the chief financial officer directly owned 172,909 shares of the company's stock, valued at $4,320,995.91. The trade was a 1.89% decrease in their position. The disclosure for this sale can be found here. 10.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Privia Health Group

Hedge funds and other institutional investors have recently bought and sold shares of the company. Acadian Asset Management LLC purchased a new stake in Privia Health Group during the first quarter valued at approximately $154,000. AQR Capital Management LLC grew its position in shares of Privia Health Group by 24.7% in the first quarter. AQR Capital Management LLC now owns 40,781 shares of the company's stock valued at $916,000 after purchasing an additional 8,068 shares during the period. Intech Investment Management LLC grew its position in shares of Privia Health Group by 55.1% in the first quarter. Intech Investment Management LLC now owns 56,553 shares of the company's stock valued at $1,270,000 after purchasing an additional 20,082 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Privia Health Group by 3.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 118,764 shares of the company's stock worth $2,666,000 after buying an additional 3,714 shares in the last quarter. Finally, Royal Bank of Canada raised its stake in Privia Health Group by 63.5% during the first quarter. Royal Bank of Canada now owns 245,633 shares of the company's stock worth $5,514,000 after purchasing an additional 95,371 shares during the period. Hedge funds and other institutional investors own 94.48% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on PRVA shares. Needham & Company LLC restated a "buy" rating and set a $30.00 target price on shares of Privia Health Group in a research note on Thursday, April 10th. JPMorgan Chase & Co. boosted their price target on shares of Privia Health Group from $29.00 to $32.00 and gave the stock an "overweight" rating in a research note on Wednesday, May 28th. Truist Financial boosted their price target on shares of Privia Health Group from $27.00 to $28.00 and gave the stock a "buy" rating in a research note on Thursday, April 10th. JMP Securities reiterated a "market outperform" rating and issued a $29.00 price target on shares of Privia Health Group in a research note on Monday, April 28th. Finally, Evercore ISI decreased their price target on shares of Privia Health Group from $30.00 to $28.00 and set an "outperform" rating on the stock in a research note on Wednesday, July 9th. One equities research analyst has rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $28.38.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.